Matt Pfeffer, the CEO of MannKind Corporation (NASDAQ:MNKD), presented in the JPMorgan Healthcare Conference. He started his presentation stating that it is a pleasure to present at this conference again. It’s been a full year compared to the last year since he attended the presentation last year, almost at this time.
The details
MannKind CEO stated that the company’s lead product, the marketed product currently, is Afrezza. It is a unique inhaled insulin that improves the glycemic control in subjects with diabetes. Now, it would be with both type of diabetic patients, type 1 and type 2. Clearly, it offers a broad scope. It was first launched in February 2015 by Sanofi, and was later discontinued.
They got this offering back right again and almost this time in previous year, after which they scrambled to essentially change the firm from mostly a supplier of the offering to Sanofi into a firm that had all the necessary commercial and infrastructure to boost an offering on the market, all the requirements from being able to target events and so forth that is needed to have a product in the industry whether you are marketing or supporting it not and then finally establishing that commercial infrastructure, comprising the sales force and so forth.
MannKind built a great team, and the management is quite proud of it. They have been able to follow some very knowledgeable and experienced people in the market starting initially with company’s Chief Commercial Officer, Mr. Mike Castagna who they lured away from Amgen. But he was confident about the product and his ability to turn it a success and they still do.
Recently, market probably witnessed and MannKind included another member from the management as the HR Head, again ex Head of HR for Amgen. However, the HR unit at Amgen was much larger than MannKind.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
